Live Attenuated Polio Vaccine Market Report 2026

The live attenuated polio vaccine market size has grown strongly in recent years. It will grow from $1.98 billion in 2025 to $2.13 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to global polio eradication initiatives, widespread adoption of oral polio vaccines, strong government-led immunization programs, early success in reducing polio transmission, support from international health organizations.

The live attenuated polio vaccine market size is expected to see strong growth in the next few years. It will grow to $2.85 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to continued eradication efforts in remaining endemic regions, rising focus on outbreak prevention, expansion of vaccination coverage in underserved populations, increased funding for public health immunization programs, growing emphasis on vaccine accessibility and affordability. Major trends in the forecast period include continued use of oral polio vaccines in mass immunization, strong focus on community-level immunity and transmission control, sustained demand in polio-endemic and high-risk regions, integration of lapv in national immunization programs, emphasis on long-lasting immunity in pediatric vaccination.

The growth of the live attenuated polio vaccine market is expected to be driven by the expansion of immunization programs in the coming years. Immunization programs are organized initiatives by governments, health organizations, or other institutions to provide vaccines to populations and prevent the spread of infectious diseases. The expansion of these programs is largely attributed to increased global awareness of the importance of disease prevention, as well as strong support from governments, international health organizations, and funding bodies. Immunization programs promote the live attenuated polio vaccine (LAPV) by ensuring broad distribution, safe administration, and high coverage to build herd immunity, prevent virus transmission, and support global polio eradication. For example, in May 2025, the UK Health Security Agency, a UK-based government agency, reported that during the 2023-2024 season, a school-based program targeting all children aged 4 to 16 years (Reception to Year 11) in England reached 52.2% of eligible children in Reception to Year 9 (3,498,576 out of 6,708,016), slightly higher than the 51.9% coverage (3,502,566 out of 6,747,523) recorded in the 2022-2023 season. Consequently, the expansion of immunization programs is contributing to the growth of the live attenuated polio vaccine market.

Major companies operating in the live attenuated polio vaccine market are concentrating on obtaining regulatory approvals to ensure their vaccines comply with the safety and efficacy standards required by health authorities worldwide. Regulatory approvals refer to the official authorization granted by government health agencies or regulatory bodies, permitting a product, such as a vaccine, to be marketed, sold, and used within a particular region or country. For example, in July 2024, Biological E, an India-based pharmaceutical and biologics company, received approval from the World Health Organization (WHO) for its novel oral polio vaccine type 2 (nOPV2), a next-generation live, attenuated oral vaccine designed to address the limitations associated with traditional oral polio vaccines. This next-generation vaccine is intended to combat circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks more efficiently than its predecessor. nOPV2 is developed with enhanced genetic stability, lowering the risk of the vaccine virus reverting to a virulent form, which has been a concern with older vaccines.

In June 2024, SK bioscience, a South Korea-based vaccine and biotech company, acquired IDT Biologika for approximately $244 million. Through this acquisition, SK bioscience aims to reinforce its vaccine development and manufacturing expertise, broadening its capabilities and service offerings to advance global health improvements and support its vision for operational growth and innovation. IDT Biologika is a Germany-based contract development and manufacturing organization specializing in viral vaccines, including live attenuated virus vaccines.

Major companies operating in the live attenuated polio vaccine market are Sanofi Pasteur, Serum Institute of India Pvt. Ltd., Biological E Limited, Indian Immunologicals Limited, Bharat Biotech International Limited, Panacea Biotec, Haffkine Biopharmaceutical, Bio Farma, Bilthoven Bio, Vabiotech, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., LG Chem Ltd., Chumakov Federal Scientific Center, Institute of Poliomyelitis and Viral Encephalitides, Statens Serum Institut, Federal State Unitary Enterprise Microgen, Pasteur Institute of Iran, Institut Pasteur de Dakar.

North America was the largest region in the live attenuated polio vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated polio vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the live attenuated polio vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the live attenuated polio vaccine market by increasing costs associated with imported raw materials, vaccine production inputs, and cold-chain logistics equipment. These impacts are more evident across monovalent and bivalent vaccines, particularly in low- and middle-income regions that depend on cross-border vaccine supply and donor-supported procurement. Public health agencies and immunization programs may face budgetary pressure due to higher procurement costs. However, tariffs have also encouraged regional vaccine manufacturing, localized supply chains, and improved self-sufficiency in vaccine production, supporting long-term immunization resilience.

The live attenuated polio vaccine market research report is one of a series of new reports that provides live attenuated polio vaccine market statistics, including live attenuated polio vaccine industry global market size, regional shares, competitors with a live attenuated polio vaccine market share, detailed live attenuated polio vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated polio vaccine industry. This live attenuated polio vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The live attenuated polio vaccine (LAPV) is an oral polio vaccine (OPV) that contains a weakened form of the poliovirus, which triggers a strong immune response without causing disease in healthy individuals. It mimics natural infection, providing long-lasting immunity and aiding in the prevention of virus transmission within communities.

The main types of vaccines in live attenuated polio vaccine are monovalent, bivalent, and trivalent. A monovalent oral polio vaccine (mOPV) is formulated to protect against a single specific type of poliovirus, either type 1, type 2, or type 3. It is administered orally, intramuscularly, or subcutaneously for various age groups, including infants (0-1 years), children (1-5 years), and adults (above 5 years). It serves a range of end users, including hospitals, clinics, public health agencies, and other healthcare providers.

The live attenuated polio vaccine market consists of sales of monovalent oral polio vaccine (mOPV), bivalent oral polio vaccine (bOPV), novel oral polio vaccine, and trivalent oral polio vaccine (tOPV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.